Bali Muralidhar
InvestorManaging Partner at Abingworth · Board director at AdvanCell · Board director at Wugen · Board director at Spruce Biosciences
London
Writes $15M – $30M checks · typically $22.5M
About
Bali Muralidhar has more than 20 years of healthcare experience spanning venture investing, R&D, clinical practice, and teaching. At Abingworth he leads the transatlantic venture and clinical co-development investment teams and chairs the firm's investment committees. He previously was a senior partner at MVM Partners in London and a member of Bain Capital's healthcare deal team. He holds a degree in clinical medicine from the University of Oxford, practiced general surgery, and earned a PhD in translational cancer research from the University of Cambridge.
Contact· self-published, not guessed
Invests in
BiotechHealthtech
Board director at AdvanCell
Intro paths
In turn, Bali can intro founders to AdvanCell's investors below.
AdvanCell's investors · 9
Co-founders at AdvanCell
Board director at Wugen
Intro paths
In turn, Bali can intro founders to Wugen's investors below.
Wugen's investors · 8
Board director at Spruce Biosciences
Intro paths
In turn, Bali can intro founders to Spruce Biosciences's investors below.
Spruce Biosciences's investors · 6
Experience
- AbingworthGlobal Head of Life Sciencescurrent2026 — present
- AbingworthManaging Partner, Chief Investment Officercurrent2022 — present
- AbingworthManaging Partnercurrent2020 — presentLondon, United Kingdom
- AbingworthPartner2019 — 2020
- British Business BankNon Executive Directorcurrent2025 — presentLondon, United Kingdom
- MVM PartnersPartner2012 — 2019London, United Kingdom
- Bain CapitalAssociate2011 — 2012
- Bain & CompanyConsultant2008 — 2011
- University of Cambridge, Downing CollegeBye-Fellow2006 — 2008
- Medical Reseach CouncilResearcher2005 — 2008Translational Cancer Cell Unit - Cambridge University
- National Health ServiceClinical Fellow2004 — 2008Cambridge, United Kingdom
Skills & more
+4 more
Start-upsLife SciencesMergers & AcquisitionsPharmaceutical IndustryFrom Bali's professional profile.
Deals · 5
Allotera Therapeutics, Inc.Board seat
via Abingworth · filed Jul 2026 · $163M raise
AdvanCellBoard seat
via Abingworth · filed Jul 2026 · $315M raise
Spruce BiosciencesBoard seat
via Abingworth · filed Oct 2025 · $50M raise
WugenBoard seat
via Abingworth · filed Jul 2021 · $37.2M raise
Onkure Therapeutics IncBoard seat
via Abingworth · filed Dec 2020 · $94.8M raise
Attribution from SEC filings, press coverage, and firm rosters.
Other disclosed investments
Led
CymaBay Therapeutics
Board seats
AlloTeraAscendPathalysR1 TxRheumaLogicsValnevaWilson Therapeutics
Sources: the firm's website · SEC Form D filings.
Colleagues at Abingworth
Network5
Investors connected to Bali in public investor directories — a warm-intro map.
Frequently asked questions
- Who is Bali Muralidhar?
- Bali Muralidhar has more than 20 years of healthcare experience spanning venture investing, R&D, clinical practice, and teaching. At Abingworth he leads the transatlantic venture and clinical co-development investment teams and chairs the firm's investment committees. He previously was a senior partner at MVM Partners in London and a member of Bain Capital's healthcare deal team. He holds a degree in clinical medicine from the University of Oxford, practiced general surgery, and earned a PhD in translational cancer research from the University of Cambridge.
- Where does Bali Muralidhar work?
- Bali Muralidhar is Managing Partner at Abingworth and Board director at AdvanCell and Board director at Wugen and Board director at Spruce Biosciences.
- What does Bali Muralidhar invest in?
- Bali Muralidhar invests in Biotech, Healthtech.
- What check size does Bali Muralidhar write?
- Bali Muralidhar typically writes checks of $15M – $30M.
- What boards does Bali Muralidhar sit on?
- Bali Muralidhar holds tracked board seats at AdvanCell, AdvanCell, AlloTera, Allotera Therapeutics, Inc., Ascend, Onkure Therapeutics Inc, Pathalys, R1 Tx, RheumaLogics, Spruce Biosciences.
- What companies has Bali Muralidhar invested in?
- Investments tracked here include CymaBay Therapeutics.
- Where did Bali Muralidhar go to school?
- Bali Muralidhar studied at University of Cambridge (PhD, Cancer biology); University of Oxford (BMBCh, Clinical medicine); University of Cambridge (MA, Medical Science).
- Does Bali Muralidhar lead rounds?
- Yes — Bali Muralidhar has led 1 tracked investment.
Same school
Also attended University of Cambridge893
.png)
+ 887 more
Also attended University of Oxford990
+ 984 more
Shared employers
Also worked at Abingworth18
+ 12 more
Also worked at MVM Partners2
Also worked at Bain Capital113
+ 107 more
Also worked at Bain & Company751
+ 745 more